On September 3, 2024, MILNE GEORGE M JR, Director at Amylyx Pharmaceuticals Inc (AMLX, Financial), purchased 100,000 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 858,571 shares of Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is engaged in the development of innovative treatments aimed at stopping the progression of neurodegenerative diseases, including ALS and Alzheimer's disease.
The shares were bought at a price of $2.2 per share, valuing the transaction at $220,000. This acquisition has increased the insider's stake significantly, reflecting a strong commitment to the company's future. The current market cap of Amylyx Pharmaceuticals Inc stands at $150.122 million.
Over the past year, MILNE GEORGE M JR has purchased a total of 100,000 shares and has not sold any shares. The insider transaction history for Amylyx Pharmaceuticals Inc shows a trend with 3 insider buys and 10 insider sells over the past year.
This insider buying activity could be a signal to investors about the potential undervaluation of the stock, as suggested by the GF Value. Investors often look at such transactions to gauge insider confidence in the company's prospects.
For more detailed valuation metrics such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further to understand the financial health and growth prospects of Amylyx Pharmaceuticals Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
